Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Somatostatin secretion by delta (δ) cells refers to the release of the peptide hormone somatostatin from specialized endocrine cells found primarily in the pancreatic islets, but also present in the stomach and intestine. Delta cells make up approximately 4–5% of pancreatic islet cells. The secretion process is stimulated by elevated glucose levels, involving closure of ATP-sensitive potassium channels, leading to membrane depolarization, increased intracellular calcium, and Ca(2+)-dependent exocytosis of somatostatin-containing granules. Somatostatin acts locally within the islet as a paracrine inhibitor of insulin and glucagon secretion, and also inhibits its own release (autocrine effect). Dysregulation of somatostatin secretion is implicated in diabetes mellitus and impaired hypoglycemia-induced glucagon response.
N/A - This entry describes a cellular process, not a specific molecule for drug targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Somatostatin Secretion by Delta Cells (SST Secretion (Delta Cells)).